MilliporeSigma Supports Eijkman Institute to Expedite Covid-19 Vaccine Development Research

• Eijkman Institute for Molecular Biology developing Covid-19 vaccine based on local strain virus strain
• Institute to receive research instruments and materials to advance production

Jakarta, Indonesia, September 3, 2020 — MilliporeSigma, a leading science and technology company, today announced the donation of research instruments and materials worth IDR 1.2 billion (€ 74,000) to support the efforts of Eijkman Institute for Molecular Biology, Indonesia, in its efforts to accelerate vaccine development research. The institute is developing a Covid-19 vaccine based on a local virus strain, in collaboration with several local research institutions.

“MilliporeSigma supplies critical products and services and provides solutions for scientists to identify and characterize viruses and develop vaccines and therapies – work that is especially important as vaccine developers race to fight Covid-19,” said Christopher Thomas, president director at MilliporeSigma in Indonesia. “Eijkman Institute’s work is promising and we are committed to supporting them.”

MilliporeSigma is donating reagents and consumables to make viral transport medium, which are tubes that store patients’ swab test samples, allowing them to be safely transported from swab sampling locations (i.e., clinics, hospitals, health centers) to testing labs. The company is also donating RiOs™ Essential water purification systems, which produce high-quality type-3 pure water by integrating pre-treatment and high-performance reverse osmosis membranes.

"The utmost priority in combating Covid-19 is accelerating the discovery of Covid-19 vaccine to protect people and breaking the chain of infection in Indonesia,” said Professor Amin Soebandrio, chairman of Eijkman Institute for Molecular Biology. “Prevention is certainly better than cure. Global partners and qualified state-of-the-art research instruments will greatly help in expediting this vaccine research. We are grateful for MilliporeSigma’s support in donating instruments and materials to help us in developing Indonesia’s Covid-19 vaccine."

Eijkman Institute’s research has progressed to the generation of sub-unit protein as the chosen platform. In general, vaccine manufacturing can take years to finish, but the institute is racing to generate the vaccine seed in only a year. It is estimated that the vaccine will be made available for further processes including clinical trials in Indonesia by early 2021.